Menu
Back to User profile » Professor Cong Xue
Papers published by Professor Cong Xue:
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
Chen Y, Li WX, Wu JH, Chen GH, Yang CM, Lu H, Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Hong RX, Jiang KK, Zhong YY, Zhang G, Tienchaiananda P, Oikawa M, Yuan ZY, Chen QJ
Breast Cancer: Targets and Therapy 2024, 16:223-231
Published Date: 12 April 2024
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma
Xue C, Tian Y, Zhang J, Zhao YY, Zhan JH, Fang WF, Zhang L
Drug Design, Development and Therapy 2016, 10:1299-1306
Published Date: 31 March 2016
Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo
Xue C, Tian Y, Zhang J, Zhao Y, Zhan J, Fang W, Zhang L
Drug Design, Development and Therapy 2016, 10:1173-1180
Published Date: 15 March 2016
Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
Zhao Y, Zhang J, Tian Y, Xue C, Hu Z, Zhang L
Drug Design, Development and Therapy 2015, 9:4897-4907
Published Date: 26 August 2015
Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma
Zhang XK, Qin T, Zeng YD, Zhao YY, Hou X, Fang WF, Hong SD, Zhou T, Hu ZH, Yang YP, Ma YX, Xue C, Huang Y, Zhao HY, Zhang L
OncoTargets and Therapy 2015, 8:1219-1227
Published Date: 26 May 2015
Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
Zhao YY, Tian Y, Zhang J, Xu F, Yang YP, Huang Y, Zhao HY, Zhang JW, Xue C, Lam MH, Yan L, Hu ZH, Dinglin XX, Zhang L
Drug Design, Development and Therapy 2014, 8:1827-1837
Published Date: 10 October 2014
Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials
Hong SD, Fang WF, Liang WH, Yan Y, Zhou T, Qin T, Wu X, Ma YX, Zhao YY, Yang YP, Hu ZH, Xue C, Hou X, Chen Y, Huang Y, Zhao HY, Zhang L
OncoTargets and Therapy 2014, 7:1851-1867
Published Date: 7 October 2014
High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis
Yuan ZY, Luo RZ, Peng RJ, Wang SS, Xue C
OncoTargets and Therapy 2014, 7:1475-1480
Published Date: 21 August 2014
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
Wu X, Liang WH, Hou X, Lin Z, Zhao HY, Huang Y, Fang WF, Zhao YY, Wu JX, Yang YP, Xue C, Hu ZH, Zhang J, Zhang JW, Ma YX, Zhou T, Qin T, Zhang L
OncoTargets and Therapy 2013, 6:1481-1491
Published Date: 21 October 2013
Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment
Zhao H, Zhao Y, Guo Y, Huang Y, Lin S, Xue C, Xu F, Zhang Y, Zhao L, Hu Z, Zhang L
OncoTargets and Therapy 2013, 6:811-818
Published Date: 3 July 2013
The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution
Zhang J, Huang Y, Li X, Guo Y, Zhao Y, Xue C, Hu Z, Zhang L, Zhao H
OncoTargets and Therapy 2012, 5:349-355
Published Date: 15 November 2012